Virus plus immunotherapy and chemo before pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of an oncolytic virus (a virus that targets cancer cells), an immunotherapy drug (anti-PD1), and chemotherapy given before surgery for people with borderline resectable or locally advanced pancreatic cancer. The goal is to see if this approach can shrink the tumor enough to make surgery more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of pancreatic cancer called borderline resectable or locally advanced.
- You have not had chemotherapy, radiation, or immunotherapy for this cancer before.
- You are in good general health (able to do normal daily activities).
- You do not have other serious medical conditions like an active infection, HIV, or uncontrolled heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
This trial tests a combination of an oncolytic virus (a virus that attacks cancer cells) and a PD-1 inhibitor (an immunotherapy drug) for people with advanced pancreatic cancer that has not responded to at least two prior treatments.
This trial tests a new drug, VRT106, combined with chemotherapy for people with advanced pancreatic cancer that has not been treated before. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.